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The high mobility group box 1 (HMGB1) is a well-known late mediator of sepsis, secreted
by multiple stimuli, involving pathways, such as the mitogen-activated protein kinase
(MAPK) and nuclear factor kappa B (NF-κB) pathways, and reactive oxygen species
(ROS) under inflammation. Sulfatide, in contrast, is a sphingolipid commonly found
in myelin sheets with a disputed immunological role. We sought to determine the
immunological characteristics of sulfatide in the periphery by analyzing the secretion
of HMGB1 triggered by lipopolysaccharide (LPS) stimulation in Raw 264.7 cells.
Suppression of HMGB1 secretion by inhibiting its cytosolic translocation was observed
after pre-treatment with sulfatide before LPS stimulation. Further analysis of the
downstream molecules of toll-like receptor (TLR) signaling revealed suppression of c-Jun
N-terminal kinase (JNK) phosphorylation and p65 translocation. LPS-mediated ROS
production was also decreased when sulfatide pre-treatment was provided, caused by
the down-regulation of the phosphorylation of activators, such as IRAK4 and TBK1.
Investigation of the upstream mechanism that encompasses all the aforementioned
inhibitory characteristics unveiled the involvement of lipid rafts. In addition to
the co-localization of biotinylated sulfatide and monosialotetrahexosylganglioside, a
decrease in LPS-induced co-localization of TLR4 and lipid raft markers was observed
when sulfatide treatment was given before LPS stimulation. Overall, sulfatide was found
to exert its anti-inflammatory properties by hindering the co-localization of TLR4 and lipid
rafts, nullifying the effect of LPS on TLR4 signaling. Similar effects of sulfatide were also
confirmed in the LPS-mediated murine experimental sepsis model, showing decreased
levels of serum HMGB1, increased survivability, and reduced pathological severity.
Keywords: sulfatide, HMGB1, TLR4, lipid raft, sepsis, NF-κB, ROS
INTRODUCTION
Approximately 45 years have passed since the HMGB1 protein, an abundant nuclear protein
and a well-defined danger-associated molecular pattern (DAMP) molecule, was first purified
(1). Since its discovery, HMGB1 has been discussed in various contexts. Nuclear HMGB1 is
well-known for its chaperone-like functions, playing a role in deoxyribonucleic acid (DNA)
Kim et al. Sulfatide Inhibits HMGB1 Secretion
unwinding (2) and DNA synthesis (3) by binding to DNA in
a sequence-independent manner (4) and in the structuring of
chromatin (5). In contrast, research regarding cytosolic HMGB1
is still in its relatively early stages, revealing its role in autophagy
regulation (6) and unconventional protein secretion (7).
HMGB1 can be either passively released through non-
apoptotic cell death, such as in necrotic cells (8), or actively
secreted through multiple pathways, such as in inflammasome-
mediated release (9). In this paper, we intend to limit the
scope to active secretion of HMGB1, triggered by inflammatory
signals transduced by toll-like receptor (TLR)-related signaling.
When TLRs are stimulated by their ligands, NF-κB (10)
and MAPK (10–12) are responsible for the translocation and
secretion of these receptors to the extracellular space. Our
research concentrates on TLR4, a member of the TLR family,
which recognizes lipopolysaccharides (LPS), and its mechanism
of action regarding the active secretion of HMGB1. Under
physiological conditions, bacterial LPS, which normally forms
a micelle, is recognized by the LPS-binding protein (LBP),
which facilitates its monomerization by CD14 (13). The LPS–
LBP complex, now bound to CD14, is then transferred to the
myeloid differentiation protein-2 (MD-2)–TLR4 complex (14).
This complex then forms a dimer, completing its activation
process. TLR4 dimers, however, require the formation of a
lipid raft, a special nano-scale membrane structure consisting of
various lipids (15). TLR4, which contains lipid-binding motifs,
is attracted and can readily form a dimer within the lipid rafts,
providing a platform on which the TLR4s can be within closer
proximity (16).
Most studies addressing the immunological role of HMGB1
have focused on the role of extracellular HMGB1 as a DAMP
molecule and its chemokine-like behavior. Depending on its
redox status, HMGB1 exerts different characteristics: 1) as
a thiol isoform, in which all of the three active cysteine
residues (Cys23, 45, and 106) are in free-thiol(-SH) form,
HMGB1 binds to C-X-C motif ligand 12 (CXCL12) and shows
chemokine-like activity, recruiting immune cells to the site of
inflammation (17); 2) the disulfide isoform of HMGB1, which
possesses one intra-molecular disulfide bond between the two
cysteinemolecules Cys23 and Cys45, exerts cytokine-like activity,
activatingmacrophages and lymphocytes (18–20); 3) the oxidized
isoform of HMGB1, containing fully oxidized cysteine residues (-
SOOOH) is considered immunologically inert (21, 22). In sepsis,
extracellular HMGB1 is known to be released in its reduced form
(23); it is considered a potent pro-inflammatory cytokine (24)
and a promising therapeutic target in clinical studies (25, 26).
Sulfatide, also known as 3-O-sulfogalactosylceramide, is a
lipid commonly found in the myelin sheath in both the central
and peripheral nervous system (27). First isolated and partially
characterized over 40 years ago (28), sulfatide was suggested
to play a varying role in physiological functions, ranging
from myelination of nerves (29, 30) to insulin secretion (31–
34). Similar to HMGB1, intracellular (or membrane-bound)
sulfatide and extracellular sulfatide play different roles. While
the intracellular (or membrane-bound) form performs the
abovementioned functions, extracellular sulfatide can bind to
selectins to cause hemostasis (35) or metastasis of tumors
(36) or bind to CD1d activating natural killer T (NKT) cells
with various anti-inflammatory abilities (37–41). Although most
papers discussing the anti-inflammatory functions of sulfatide
emphasize on NKT cells, a report suggested that sulfatide may
have a direct effect on brain-resident immune cells, causing
inflammation (42). This discrepancy between immune cells
residing in the central or peripheral nervous system led us to
investigate the direct effect of sulfatide in peripheral immune
cells, namely the macrophages.
In this study, we aimed to elucidate the effect of sulfatide in the
context of innate immunity by investigating its effect on HMGB1
secretion under LPS stimulus and discuss the specific molecules
involved in the process.
MATERIALS AND METHODS
Cell Culture and Treatment Reagents
Raw 264.7 cells were cultured in Dulbecco’s Modified Eagle’s
Medium supplemented with 10% heat-inactivated fetal bovine
serum (Gibco, Waltham, MA, USA), 100µg/mL of penicillin,
and 100µg/mL of streptomycin (Sigma, Saint Louis, MO, USA).
Treatment was performed after allowing the cells to adapt to
Opti-MEM (Gibco) for 2 h, after which the media was replaced.
LPS (Escherichia coli O111:B4; > 3 x 106 EU/mL; Sigma),
sulfatide (Bovine; brain; Matreya, State College, PA, USA),
18:0(2R-OH) sulfogalactosylceramide (synthetic; Avanti,
Alabaster, AL, USA), C24:0 mono-sulfogalactosylceramide
(synthetic; Avanti), C24:0 mono-sulfogalactosylceramide
(synthetic; Avanti), galactosylceramide (Bovine; Matreya), and
ceramide (Bovine; Matreya) were used as indicated in the




Wild-type C57BL/6 mice obtained from Orient Bio (Seongnam,
Gyeonggi-do, South Korea) were housed in a SPF-grade facility
with controlled temperature, humidity, and light. For all
experiments, 8-week old female mice with approximate body
weight of 20 g were used. The animals were ethically sacrificed,
and the femur and tibia were extracted. Bone marrow was
collected via warm, serum-free DMEM lavage until no remaining
bone marrow was visible. Bone marrow was collected and
filtered through cell strainer with 40µm pore (SPL, Pocheon-si,
Gyeonggi-do, South Korea) to remove any undesirable debris and
washed with excessive media to further remove unfiltered debris.
The resulting cells were plated to 100mm cell culture-treated
dish (Corning, Oneonta, NY, USA), and then differentiated
using 20 ng/mL GM-CSF in complete medium for 7 days to
yield BMDMs.
Sample Preparation (Culture Media)
Culture media after treatment were collected after 24 h to
compare HMGB1 secretion between groups. Culture media
were then centrifuged at 3500 × g for 5min to remove any
cell debris. The supernatant was collected for trichloroacetic
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acid (TCA)/acetone precipitation. Then, 10% by volume of ice-
cold TCA was added to the samples and mixed by inverting.
After incubating overnight at−20◦C, the samples were thawed
and centrifuged at 20000 × g for 90min. Supernatants were
then discarded. The remaining pellets were washed with−20◦C
acetone by vortexing vigorously and left overnight at−20◦C.
Samples were centrifuged at 20000 × g for 90min, and the
resulting supernatants were removed. The remaining pellets were
then dried and boiled with 2X sample buffer.
Sample Preparation (Whole Cell Lysate)
Cells were harvested by scraping using cold Dulbecco’s phosphate
buffered saline (PBS) after the indicated time periods; they were
then collected by centrifuging at 3000× g for 5min. Supernatants
were discarded, and radioimmunoprecipitation (RIPA) buffer
was added before sonication. Lysed cells were centrifuged at
20000 × g for 10min to remove any debris. The resulting
whole cell lysates were collected, and protein concentration was
quantified using the bicinchoninic acid (BCA) assay. The cell
lysates were then prepared by heating to 65◦C for 10min after
adding sample buffer to minimize the loss of phosphorylated
protein to beta-elimination.
Western Blot
SDS-PAGE was performed on samples prepared via the
abovementioned methods, and proteins were transferred to
a polyvinylidene difluoride (PVDF) membrane for western
blotting. Transferred membranes were blocked using 5%
skimmed milk. Primary antibodies for HMGB1 (Abcam;
Cambridge, UK), JNK (phospho- and whole; Cell Signaling
Technology; Danvers, MA, USA), ERK1/2 (phospho- and
whole; Cell Signaling Technology), p38 (phospho- and whole;
Cell Signaling Technology), phospho-IκBα (Cell Signaling
Technology), phospho-IRAK4, phospho-TBK1 (Cell Signaling
Technology), caveolin 1 (Merck; Darmstadt, Germany), TLR4
(Santa Cruz; Dallas, TX, USA), and β-actin (Santa Cruz) were
diluted in 5% skimmed milk solution and incubated overnight
at 4◦C. After extensive washing, the corresponding secondary
antibody solutions were incubated for 1 h at room temperature
(20∼25◦C). The membranes were then washed, and signals were
detected using enhanced chemiluminescence substrate solution
(Gendepot; Katy, TX, USA) and X-ray film (AGFA; Mortsel,
Belgium). Membranes were stripped using stripping solution
(BioMax, Seoul, South Korea) for re-blotting, as necessary.
Densitometry analysis was performed using Image J.
Immunofluorescence
Raw 264.7 cells were seeded in 4-well chambered glass
slides coated with poly-L-lysine (Sigma). Treatment dosage
for LPS was increased to 200 ng/mL to facilitate visualization
via immunofluorescence, and sulfatide dosage was adjusted
accordingly to maintain molar ratio. Treatment was performed
for the duration indicated in Figure Legends. After treatment,
cells were then fixed with 4% paraformaldehyde overnight in
4◦C. On the subsequent day, the cells were washed with PBS
and permeabilized with 1% Triton X-100 and blocked with
bovine serum albumin (BSA). Primary antibodies anti-p65 (Santa
Cruz) or anti-HMGB1 (Abcam) were diluted in BSA solution
and left to incubate overnight at 4◦C. After thorough washing,
the respective secondary antibodies conjugated with Alexa Fluor
488 (Invitrogen; Waltham, MA, USA) were diluted in BSA
solution and incubated at 37◦C for 45min. Slides were then
washed, dried, andmounted usingmountingmedium containing
4′,6-diamidino-2-phenylindole (DAPI; Vector). Sealed slides
were observed via FV1000 confocal microscopy (Olympus).
Localization of sulfatide was determined by treating Raw 264.7
cells with biotin-sulfatide and staining them with streptavidin-
Alexa Fluor 488 (Invitrogen). Localization of TLR4 was detected
using mouse anti-TLR4 antibodies (Invitrogen).
ROS Detection
Raw 264.7 cells were pre-treated with either vehicle control or
20µM of sulfatide and with vehicle control or 100 ng/mL of
LPS for 1 h. The treatment medium was removed, and culture
dishes were washed twice with warm culture medium. H2-
DCFDA (Thermo Fisher; Waltham, MA, USA) was treated as
per the manufacturer’s instructions. Cells were viewed under a
fluorescence microscope. For flow cytometric analysis of ROS
levels, the cells were detached before H2-DCFDA treatment.
Lipid Raft Staining
Raw 264.7 cells were seeded in 4-well chambered glass slides
coated with poly-L-lysine (Sigma). Treatment dosage for LPS
was increased to 1µg/mL to maximize lipid raft formation and
facilitate visualization via immunofluorescence, and sulfatide
dosage was adjusted accordingly to maintain molar ratio.
Treatment was performed for the duration indicated in Figure
Legends. After treatment, the cells were then washed once with
4◦C complete growth medium. Washed cells were incubated in
cholera toxin B-Alexa Fluor 549 (Invitrogen) staining solution,
prepared in 4◦C complete growth medium. Cells were washed
with ice-cold PBS three times and fixed with ice-cold 4%
paraformaldehyde for 15 min.
Lipid Raft Isolation
Raw 264.7 cells were treated with reagents for 8min as indicated
in the legends, and cells were briefly washed three times with
ice-cold PBS to halt the internalization of lipid rafts. Cells were
then lysed using the ice-cold buffer provided by Caveolea/Rafts
Isolation Kit (Merck) supplemented with Triton X-100. Lysates
then underwent ultracentrifugation with OptiPrepTM density
gradient, provided by the aforementioned kit, and nine fractions
were collected. Collected fractions were then supplemented with
1% SDS to assist complete dissociation of the protein from the
lipids. Treated samples were concentrated using TCA/Acetone
and analyzed by immunoblotting.
Animal Experiments
Wild-type C57BL/6 mice obtained from Orient Bio (Seongnam,
South Korea) were housed in a SPF-grade facility with controlled
temperature, humidity, and light. For all experiments, 8-
week old female mice were used. For serum collection, mice
were anesthetized using an isoflurane–oxygen mixture, and
combinations of PBS, LPS (3 mg/kg), or sulfatide (25 nmol)
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were injected with a total of 100 µL injection volume,
intraperitoneally. The animals were allowed 60min between
injections to fully recover from the effects of anesthesia. Serum
samples were collected after 18 h. Survival rate was measured
by following the same procedure as mentioned above, with
increased doses of LPS and sulfatide injection (to 20 mg/kg
and 175 nmol, respectively). Mice were checked twice every
day and observed until completion. Survival data were then
analyzed through Kaplan-Meier survival analysis. Pathological
scores were obtained using the scoring regimen described
by Shrum et al. (43), and the obtained scores were then
analyzed through ANOVA and Dunnett’s multiple comparison
FIGURE 1 | Sulfatide inhibits HMGB1 translocation and release in Raw 264.7 cells. (A) Dose-dependency of sulfatide regarding HMGB1 secretion was accessed 24 h
after LPS treatment. Varying dosage of sulfatide was treated 10min prior to LPS treatment. (B) Efficacy of sulfatide pre-treatment for indicated time on HMGB1
secretion and its effect after removal of sulfatide was observed. Washed cells received two 36◦C PBS wash to remove the residual sulfatide prior to LPS treatment,
whereas unwashed cells were left unperturbed. (SE, Short Exposure; LE, Long Exposure) (C) Raw 264.7 cells received vehicle control, LPS 200 ng/mL, sulfatide
40µM only, or 10min of sulfatide 40µM pre-treatment, followed by LPS 200 ng/mL for 6 h. Cells were fixed for analysis by immunofluorescence, as described in the
Methods section. In total, 100 cells were counted, and those containing HMGB1 signals in the cytoplasm were counted as positive. (D) Culture media were analyzed
by ELISA for TNF-α and IL-6 titer. Cells were treated with vehicle control (PBS with DMSO), LPS 100 ng/mL, or 10min of sulfatide 20µM pre-treatment, followed by
LPS 100 ng/mL. Graphs show the mean value and error bars of three independent experiments performed. *p < 0.01, **p < 0.001.
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test. All experiments were conducted according to procedures
approved by the Institutional Animal Care and Use Committee




Tumor necrosis factor α (TNF-α) and interleukin-6 (IL-
6) ELISA were performed using Raw 264.7 cell culture
medium. Cells were treated with vehicle control (negative
control), 100 ng/mL LPS, and sulfatide 20µM, followed by
LPS 100 ng/mL. Culture media were collected after 12 h of
treatment and centrifuged to remove any cell debris. ELISA
was performed with the resulting supernatant following the
manufacturer’s instructions (Invitrogen). Serum obtained from
murine experimental sepsis models was analyzed for HMGB1
levels with a HMGB1 ELISA kit (IBL International), following the
manufacturer’s instructions.
Statistical Analysis
Unless specified otherwise, statistical analysis of experimental
data present in this paper were performed with Student’s t test
and ANOVA, with Tukey’s multiple comparison test as post-hoc
test, using GraphPad Prism 5. The data represent the mean value
and SD. The difference was considered statistically significant at
p < 0.05.
RESULTS
Sulfatide Inhibits HMGB1 and
Pro-inflammatory Cytokines Release
To study whether sulfatide treatment shows pro-inflammatory
or anti-inflammatory characteristics, we analyzed the secretion
level of a well-known DAMP molecule, HMGB1. When
treated simultaneously, sulfatide exhibited an inhibitory effect
in HMGB1 secretion without toxicity in a dose-dependent
manner, as shown (Figure 1A, Supplementary Figure 1A).
This phenotype was unique to sulfatide, and was not
seen in its precursors, galactosylceramide, and ceramide
(Supplementary Figure 1B). Further analysis using ligands of
other extracellular TLRs shows complete inhibition of HMGB1
secretion (Supplementary Figure 1C). This indirectly suggests
that the anti-inflammatory effect does not come from inhibiting
the ligand-receptor interaction by acting as a competitive
inhibitor or aggregating reagent against TLR ligands, since it
is unlikely that a molecule can act as broad-range inhibitor or
aggregating reagent against multiple TLR ligands with different
characteristics. Next, the time point-dependent effect of sulfatide
was studied to further investigate the mechanism of action
(Figure 1B). Interestingly, sulfatide not only exhibited dose- and
time-dependent manner in HMGB1 release suppression, but
also removal of sulfatide only induced a slight increase—lower
than the secretion level of negative control, nevertheless—
in HMGB1 secretion in 6 and 12 h-pretreatment samples.
These results, combined with the results collected above,
FIGURE 2 | Sulfatide suppresses NF-κB activation and JNK phosphorylation. (A) Raw 264.7 cells received vehicle control, LPS 200 ng/mL, sulfatide 40µM, or 10min
of 40µM sulfatide pre-treatment, followed by LPS 200 ng/mL for 40min. Cells were then fixed for analysis by immunofluorescence as described in the Methods
section. In total, 100 cells were counted, and those with p65 signals co-localizing with DAPI were counted as positive. *p < 0.001. (B,C) Raw 264.7 cells received
vehicle control, LPS 100 ng/mL, sulfatide 20µM, or 10min of 20µM sulfatide pre-treatment followed by LPS stimuli, as shown in the figure. Cells were harvested after
the indicated times and analyzed for the phosphorylation level of IκBα (B), p-ERK, p-JNK, and p-p38 (C) by immunoblotting.
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suggest that sulfatide is neither an aggregating reagent nor
competitive inhibitor, nor a reversible non-competitive inhibitor
of TLR ligands.
Although multiple points of inhibition are potentially
available throughout the HMGB1 secretion pathway, they
can be categorized into two large categories: initial signal
transduction, and the release step. In order to clarify whether
sulfatide affects the former or the latter, we treated Raw
264.7 cells with LPS or sulfatide and investigated HMGB1
localization via immunofluorescence microscopy (Figure 1C).
Confocal microscopy images show sulfatide inhibits nuclear
HMGB1 translocation to the cytoplasm caused by LPS
stimulation. This indicates that the inhibition mechanism
of sulfatide does not target the release of HMGB1 to the
extracellular space itself, but the pathway that precedes
HMGB1 translocation.
Previous reports state sulfatide to play a pro-inflammatory
role in brain-resident immune cells (42). In order to confirm
its anti-inflammatory characteristics shown within our
experimental setup, we treated Raw 264.7 cells with vehicle
control, LPS alone, or LPS stimuli after sulfatide pre-treatment
(Figure 1D). Contrary to previous reports made with brain-
resident immune cells, sulfatide did not induce any significant
secretion of pro-inflammatory cytokines, namely TNF-α and
IL-6. Interestingly, a combination of LPS and sulfatide, however,
did result in a significant decrease in the secretion levels of
both TNF-α and IL-6, indicating that sulfatide indeed has an
anti-inflammatory role in the peripheral immune system.
FIGURE 3 | Sulfatide down-regulates LPS-induced ROS production. Raw 264.7 cells were treated with 20µM sulfatide or vehicle control for 10min prior to receiving
LPS 100 ng/mL, and were analyzed through (A) flow cytometry and (B) fluorescence microscopy. More than 150 cells were counted. *p < 0.001. (C) Cells were
pre-treated with vehicle control or 20µM sulfatide before treatment with 100 ng/mL LPS. Cells were lysed, and the samples were immunoblotted for p-TBK1 and
p-IRAK4. Numbers below the immunoblots represent the relative band intensity, obtained by densitometry analysis. Vehicle controls of each groups were considered
as standards.
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Sulfatide Down-Regulates NF-κB Signaling
Pathway and JNK Phosphorylation
The pathway most frequently associated with TLR signaling,
NF-κB signaling pathway, is a cascade of signaling molecules
that results in the degradation of NF-κB inhibitory molecules
and the translocation of NF-κB to the nucleus, acting as a
transcription factor. Concerning this pathway, we performed
immunofluorescence microscopy, tracking the location of the
p65 molecule, and immunoblotting of the IκBα molecule
(Figures 2A,B). Our immunofluorescence data shows that NF-
κB activation, signified by the translocation of p65, decreased
when cells were pre-treated with sulfatide. Immunoblotting
also indicated that phosphorylation of IκBα, a crucial step
that precedes its ubiquitination and degradation, significantly
decreases when pre-treated with sulfatide.
Further analysis of the MAPKs within the TLR signaling
pathway revealed specific kinases affected by sulfatide treatment.
The phosphorylation levels of ERK, JNK, and p38 MAPK
were analyzed via immunoblotting (Figure 2C). Immunoblots
revealed that only the phosphorylation level of JNK, but not
of ERK or p38, was decreased by pre-treatment with sulfatide.
Overall, sulfatide blocks the NF-κB signaling pathway and
JNK-mediated HMGB1 translocation.
LPS-Mediated ROS Production Is
Decreased by Sulfatide
Since an alternate mechanism exists, where HMGB1 release
can be triggered via LPS-TLR4 signaling through ROS
production, we sought to measure the changes in the level
of intracellular ROS in the presence/absence of sulfatide
pre-treatment (Figures 3A,B). Flow cytometric analysis
and measurement of relative fluorescence intensity both
show a significant decrease in intracellular ROS levels
in sulfatide pre-treated groups. Such a decrease in ROS
levels can be accredited to the decreased phosphorylation
of both TBK1 and IRAK4, molecules that play crucial
roles in the regulation of NOX activity (Figure 3C). These
results, paired with those presented in earlier experiments,
propose that the point of inhibition, which sulfatide utilizes
to suppress HMGB1 release is positioned higher in the
signaling hierarchy.
Sulfatide Hinders the Translocation of
TLR4 Into Lipid Rafts
We hypothesized that sulfatide, a well-known component of
the cell membrane, may interfere with the lipid composition
of the cell membrane, inhibiting its signaling pathways. Since
FIGURE 4 | TLR4–lipid raft complex formation is reduced by sulfatide. (A) Raw264.7 cells were treated with 200µM of biotinylated sulfatide, with or without 1µg/mL
of LPS for 8min. Biotinylated sulfatide was stained with streptavidin-Alexa Fluor 488 and TLR4 with anti-rabbit-Alexa Fluor 549, and the cells were prepared for
confocal microscopy as described in the Methods section. (Scale bar : 10µm) (B) Raw 264.7 cells were treated with vehicle control or 40µM of sulfatide for 10min,
before 8min of vehicle control or 200 ng/mL of LPS treatment. (C) Raw 264.7 cells were identically treated as those in (B), and obtained samples were immunoblotted
for TLR4 and caveolin 1. All membranes were immunoblotted under identical medical X-ray film for accurate comparison. (SE, Short Exposure; LE, Long Exposure).
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TLR4 requires its monomers to be localized within the lipid
raft microdomains to form dimers, we sought to assess (1)
whether sulfatide localizes to the lipid raft microdomains, and
(2) whether sulfatide treatment curbs the localization of TLR4 to
lipid rafts. Utilization of biotinylated sulfatide revealed the co-
localization of sulfatide and lipid rafts (Figure 4A), indicating
the possibility of direct involvement of sulfatide in the lipid
raft machinery. Next, to observe the co-localization of TLR4
and lipid rafts, we treated cells with appropriate stimuli and
were prepared for immunofluorescence. Results insinuated that
sulfatide plays a role in significantly decreasing the localization
of TLR4 into the lipid microdomains. Such findings were
reinforced by subjecting the cells to identical conditions and
fractionating the cell lysate for lipid rafts. Results showed
significantly decreased co-localization of TLR4 within the lipid
raft fractions, signified by caveolin-1, in sulfatide-treated groups.
In summary, sulfatide was found to interfere with the localization
of TLR4 within lipid rafts, decreasing the efficacy of TLR4
signaling (Figures 4B,C).
Relase of HMGB1 Is Suppressed by
Sulfatide in BMDM and the Murine
Experimental Sepsis Model
The effects of sulfatide in primary cells and in vivomurinemodels
were measured. BMDMs of 8 weeks old female C57BL/6 mice
were harvested and were subjected to the same stimuli used
above (Figure 5A). BMDMs pre-treated with sulfatide showed
significantly decreased HMGB1 secretion, compared to cells
treated with LPS alone, congruent with data obtained with Raw
263.7 cells. Such conformity led us to induce an experimental
septic shock by the means of a sub-lethal dose injection of
LPS into the peritoneum of C57BL/6 mice. Measurement of
serum HMGB1 level was taken from sera obtained from a total
of 18 mice (Figure 5B). Serum HMGB1 level was significantly
decreased in the groups pre-treated with sulfatide, compared to
groups treated only with LPS (Figure 5B). These results show
that sulfatide regulates the release of HMGB1, a late time point
cytokine of sepsis, in the murine experimental sepsis model. Such
decrease in the serumHMGB1 level is also reflected in themurine
FIGURE 5 | Sulfatide decreases HMGB1 release in mouse BMDMs and the murine experimental sepsis model. (A) BMDMs were subjected to vehicle control, LPS
100 ng/mL, and 10min of 20µM sulfatide pre-treatment, followed by LPS 100 ng/mL for 24 h. The dotted line indicates where different portion of the identical
membrane have been presented together. (B) C57BL/6 mice (7 mice per group) were intraperitoneally injected with PBS, LPS, or sulfatide pre-treatment, followed by
LPS injection, as discussed in the Methods section. Sera were harvested and prepared for ELISA to measure serum HMGB1 level. (C) C57BL/6 mice (5 mice per
group) were subjected to a survival test against LPS-induced lethal septic shock. Two independent trials were completed, and the results were pooled for statistical
analysis. (D) A pathological score was obtained from the mice described in (C). Mice from the second trial were used. *p < 0.01, **p < 0.001, ***p < 0.0001.
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model injected with a lethal dosage of LPS, mimicking acute
septic shock. Although showing the telltale signs of septic shock
(decreased physical activity, shivering etc.), mice pre-injected
with sulfatide before LPS injection experienced no death in the
population, in contrary to those that received saline pre-injection
(Figure 5C). Additionally, to accurately compare the severity
of the septic shock and the effect of sulfatide in decreasing its
severity, pathological scores were measured every 24 h. Sulfatide
pre-injected mice showed similar increase in pathological scores
as the mice injected only with LPS for the first 24 h; however,
groups that only received LPS injection showed a continuous
increase in pathological scores, whereas the scores of the sulfatide
pre-injected group plateaued, followed by a decrease in the
pathological score (Figure 5D). Generally, sulfatide successfully
blocked the LPS-mediated HMGB1 release in sepsis, decreasing
the level of serum HMGB1 and preventing severe symptoms and
death caused by sepsis.
DISCUSSION
Our experiments showed sulfatide reducing HMGB1 secretion
and cytosolic translocation upon LPS stimulation. Sulfatide
decreased the activation of NF-κB translocation into the nucleus,
and inhibition of multiple kinases, such as JNK, IRAK4, and
TBK1, was also seen throughout the experiment. JNK is a well-
known signaling molecule playing a crucial role in cellular
stress conditions, and when activated, phosphorylated JNK can
also alter the mitochondria to increase its ROS production
significantly, creating a positive feedback loop (44). Mice
expressing inactive mutant form of IRAK4 were found to be
more susceptible to Listeria monocytogenes and Mycobacterium
smegmatis systemic infections due to impaired induction of
inducible nitric oxide synthase (iNOS) mRNA (45). Since TBK1
was also involved in mitophagic regulation of mitochondrial
physiology and expression of iNOS mRNA during inflammatory
assault, paired with the reduction of ROS production, we
hypothesized that the inhibitory characteristics of sulfatide may
come from the upper hierarchy (46, 47). Further experiments
showed sulfatide was hindering the lipid raft–TLR4 interaction,
thereby diminishing the TLR4 signaling pathway (Figure 6).
Based on our research, the possibility of exogenous sulfatide
as regulator of lipid raft—receptor complex formation may be
suggested in clinical scenarios, in addition to the experimental
sepsis model provided within. Pathological action of angiotensin
II, a potent vasoconstrictor which binds to the AT1 receptor, are
ascribed to multiple vascular diseases, such as hypertension and
secondary cardiac hypertrophy (48). AT1 receptors are reported
to be associated with lipid rafts (49); thus, sulfatide can be
used to alter the lipid composition of the microdomains to
deter the pathology in angiotensin II-mediated hypertension
patients. Moreover, the immunological synapse, crucial for
B/T cell activation, also depends on lipid raft formation
(50–53), proposing a potential treatment strategy against
autoimmune diseases such as rheumatoid arthritis, Type I
diabetes, and multiple sclerosis (54–56) by blocking abnormal
B/T cell activation.
FIGURE 6 | Schematic summary of the proposed mechanism of action.
Sulfatide, however, has been reported as a possible auto-
antigen in multiple sclerosis and experimental autoimmune
encephalomyelitis (EAE). Lipid microarrays showed specific
antibodies against various lipids in the cerebrospinal fluid,
including ones against sulfatide in the murine EAE model and in
multiple sclerosis (57, 58). Kanter et al. also reported the increase
in disease severity as the mice were immunized with sulfatide
and myelin membrane proteins. A further role of sulfatide as a
pro-inflammatory molecule in pathogenesis was discovered in
autoimmune hepatitis (59). In contrast, the anti-inflammatory
roles of sulfatide were also revealed in autoimmune neuritis
and asthma, mediated by sulfatide-activated type II NKT cells
(37, 60). These reports suggest that sulfatide can be a double-
edged sword, depending on the organ and pathological context,
and that caution must be taken when attempting to adapt the
“natural” form of sulfatide as a potential therapeutic agent.
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Further studies regarding the mechanism of action of sulfatide in
the abovementioned pathologies should be pursued to minimize
or ameliorate side effects, possibly by utilizing small molecules
mimicking the action of sulfatide.
Our research was able to report the anti-inflammatory
effect of sulfatide in the periphery, specify the kinases within
the NF-κB and MAPK pathway affected by sulfatide, and
elucidate its mechanism of action. Sulfatide, nevertheless, is
naturally a mixture of varying lengths of carbon chain backbone;
therefore, the sulfatide used in this experiment is close to its
natural form but far from being homogenous. Such properties
could control the accessibility of sulfatide isoforms to various
molecules via steric hindrance and variation in affinity. The
composition of sulfatide isoforms has been connected to MS
prognosis, enabling physicians to differentiate remitting MS
from progressive MS by studying the composition of sulfatide
isoforms (61). Although we were able to discover sulfatide
hampering the localization of TLR4 and lipid rafts in our
research, the specific roles of each component of sulfatide
are yet to be discovered. According to the composition sheet
provided by the supplier, C24-related isoforms were dominant
in the making of sulfatide. This may explain the difference in
phenotype between our experiment and others, as we carefully
suggest the difference stems from the variability of sulfatide
composition, depending on the provider. Isaac et al. has reported
the importance of C18 sulfatide in astrocyte functionality
(62), whereas many researchers including Buschard et al. and
Blomqvist et al. have reported the crucial role of the C16:0
isoform in diabetes mellitus (63, 64). Such reports describing
distinct role of various sulfatide components could be used
to aid in indirectly understanding the phenotype difference
between our group and the others. We sought to specify the
isoform solely responsible for the phenotype shown within C24-
related isoforms and C18 sulfatide, but to no avail (data not
shown). Although we were not able to establish the isoform of
sulfatide that is responsible for its properties, we were able to
suggest that the mixture of C24-related isoforms and the C18
isoform that mimics the natural composition of sulfatide could
also mimic its suppressive phenotype (Supplementary Figure 2).
Fine-tuning the composition of specific isoforms by the means
of supplementing the patients with sulfatide isoforms as needed
may prove to be useful to alter the overall phenotype of sulfatide,
further opening its therapeutic potential.
In conclusion, our study showed the effect of sulfatide in
suppressing the secretion of HMGB1 under LPS stimulation,
and its potential as anti-sepsis treatment. We have also firstly
described the mechanism of inhibition where sulfatide inhibits
the localization of TLR4 within the lipid microdomains,
nullifying LPS-TLR4 signaling cascade. Further investigations
regarding the interaction of exogenous sulfatide with lipid
microdomains, importance of sulfatide isoform composition
in various inflammatory diseases, and in-depth studying of
isoform lipid biology are necessary to pursue future therapeutic
applications of sulfatide.
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